MCL1 and B-cell chronic lymphocytic leukemia: In accordance, AG9 (10 μM) markedly blocked type I IFN-mediated CLL cell survival (Figure 3a) by downregulating the protein levels of STAT3 and Mcl-1 (Figure 3b).